TY - JOUR
T1 - High Availability of the a7-Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment
T2 - A Pilot Study Using 18F-ASEM PET
AU - Coughlin, Jennifer M.
AU - Rubin, Leah H.
AU - Du, Yong
AU - Rowe, Steven P.
AU - Crawford, Jeffrey L.
AU - Rosenthal, Hailey B.
AU - Frey, Sarah M.
AU - Marshall, Erica S.
AU - Shinehouse, Laura K.
AU - Chen, Allen
AU - Speck, Caroline L.
AU - Wang, Yuchuan
AU - Lesniak, Wojciech G.
AU - Minn, Il
AU - Bakker, Arnold
AU - Kamath, Vidyulata
AU - Smith, Gwenn S.
AU - Albert, Marilyn S.
AU - Azad, Babak Behnam
AU - Dannals, Robert F.
AU - Horti, Andrew
AU - Wong, Dean F.
AU - Pomper, Martin G.
N1 - Funding Information:
This work was supported by the Henry N. Wagner, Jr., Endowment, a Johns Hopkins Doris Duke Foundation Early Clinician Investigator Award, and the Johns Hopkins Alzheimer Disease Research Center (P50 AG005146). No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
© 2020 Society of Nuclear Medicine Inc.. All rights reserved.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Emerging evidence supports a hypothesized role for the α7-nicotinic acetylcholine receptor (α7-nAChR) in the pathophysiology of Alzheimer's disease. 18F-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-18F-fluorodibenzo[b,d]thiophene 5,5-dioxide) is a radioligand for estimating the availability of α7-nAChR in the brain in vivo with PET. Methods: In this cross-sectional study, 14 patients with mild cognitive impairment (MCI), a prodromal stage to dementia, and 17 cognitively intact, elderly controls completed 18F-ASEM PET. For each participant, binding in each region of interest was estimated using Logan graphical analysis with a metabolite-corrected arterial input function. Results: Higher 18F-ASEM binding was observed in MCI patients than in controls across all regions, supporting higher availability of α7-nAChR in MCI. 18F-ASEM binding was not associated with verbal memory in this small MCI sample. Conclusion: These data support use of 18F-ASEM PET to examine further the relationship between α7-nAChR availability and MCI.
AB - Emerging evidence supports a hypothesized role for the α7-nicotinic acetylcholine receptor (α7-nAChR) in the pathophysiology of Alzheimer's disease. 18F-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-18F-fluorodibenzo[b,d]thiophene 5,5-dioxide) is a radioligand for estimating the availability of α7-nAChR in the brain in vivo with PET. Methods: In this cross-sectional study, 14 patients with mild cognitive impairment (MCI), a prodromal stage to dementia, and 17 cognitively intact, elderly controls completed 18F-ASEM PET. For each participant, binding in each region of interest was estimated using Logan graphical analysis with a metabolite-corrected arterial input function. Results: Higher 18F-ASEM binding was observed in MCI patients than in controls across all regions, supporting higher availability of α7-nAChR in MCI. 18F-ASEM binding was not associated with verbal memory in this small MCI sample. Conclusion: These data support use of 18F-ASEM PET to examine further the relationship between α7-nAChR availability and MCI.
KW - 18F-ASEM
KW - PET
KW - cholinergic
KW - dementia
KW - nAChR
UR - http://www.scopus.com/inward/record.url?scp=85081117280&partnerID=8YFLogxK
U2 - 10.2967/JNUMED.119.230979
DO - 10.2967/JNUMED.119.230979
M3 - Article
C2 - 31420499
AN - SCOPUS:85081117280
SN - 0161-5505
VL - 61
SP - 423
EP - 426
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 3
ER -